Investment, Funding & Disinvestments

Previously, patients requiring tests unavailable at the hospital had to wait while their samples were transported to facilities in Mbarara.

The investment at Naivasha SEZ is expected to contribute to technology transfer, skills development and job creation while strengthening Kenya’s pharmaceutical manufacturing capacity.

The deal will give BioMarin access to ALE1, Alesta’s lead clinical-stage candidate for hypophosphatasia (HPP), a rare genetic bone disorder.

This expansion enhances its capability to produce high-potency active pharmaceutical ingredients (HPAPIs), antibody-drug conjugate (ADC) payloads, and commercial small-molecule APIs.

The Sepion 75 completes Syntegon’s established Sepion tablet coating range and is designed to support consistent scale-up, flexible batch processing and containment-focused manufacturing.

The company recorded non-IFRS net profit of RMB 97.23 million (US$13.7 million), while its IFRS net loss narrowed 98% year-on-year. Everest ended the period with RMB 1.859 billion (US$261.8 million) in cash.

Under the milestone-based agreement, Sandoz could pay Henlius up to US$322 million, including near-term payments of up to US$100.5 million linked to the initial assets.

OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.

The summit will examine reforms covering healthcare financing, primary and specialised care, health commodities, digital health, the health workforce, and maternal and newborn health.

The agreement gives Zealand $50 million upfront, with another $50 million payable one year later.